Acorda Therapeutics Responds To Third Point Letter

HAWTHORNE, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (NASDAQ:ACOR) announced today that it has received a letter from Third Point LLC dated February 22, 2007. The Company has responded to Third Point as follows: The board of directors of Acorda Therapeutics continually evaluates ways to maximize shareholder value and to serve the best interests of all shareholders.

Back to news